Janney Montgomery Scott LLC boosted its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 4.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 192,669 shares of the biopharmaceutical company’s stock after purchasing an additional 7,836 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Celgene Corporation were worth $25,022,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in CELG. Waldron LP raised its stake in Celgene Corporation by 48.9% during the first quarter. Waldron LP now owns 5,207 shares of the biopharmaceutical company’s stock valued at $640,000 after purchasing an additional 1,709 shares in the last quarter. Crestwood Advisors Group LLC raised its stake in Celgene Corporation by 75.2% during the first quarter. Crestwood Advisors Group LLC now owns 4,231 shares of the biopharmaceutical company’s stock valued at $526,000 after purchasing an additional 1,816 shares in the last quarter. Personal Capital Advisors Corp raised its stake in Celgene Corporation by 11.3% during the first quarter. Personal Capital Advisors Corp now owns 233,811 shares of the biopharmaceutical company’s stock valued at $29,014,000 after purchasing an additional 23,686 shares in the last quarter. First Manhattan Co. raised its stake in Celgene Corporation by 2.7% during the first quarter. First Manhattan Co. now owns 144,148 shares of the biopharmaceutical company’s stock valued at $15,067,000 after purchasing an additional 3,853 shares in the last quarter. Finally, Sigma Planning Corp raised its stake in Celgene Corporation by 17.7% during the first quarter. Sigma Planning Corp now owns 4,814 shares of the biopharmaceutical company’s stock valued at $599,000 after purchasing an additional 723 shares in the last quarter. 79.33% of the stock is currently owned by institutional investors.

Shares of Celgene Corporation (NASDAQ CELG) opened at 142.04 on Monday. Celgene Corporation has a 52-week low of $96.93 and a 52-week high of $142.69. The firm’s 50 day moving average is $134.97 and its 200 day moving average is $127.46. The stock has a market capitalization of $111.12 billion, a price-to-earnings ratio of 43.99 and a beta of 1.89.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a return on equity of 68.51% and a net margin of 21.35%. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same period in the previous year, the company posted $1.44 earnings per share. The business’s revenue for the quarter was up 18.7% on a year-over-year basis. Equities analysts expect that Celgene Corporation will post $7.33 earnings per share for the current year.

In related news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Michael A. Friedman sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $132.50, for a total value of $1,325,000.00. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $662,500. The disclosure for this sale can be found here. Over the last three months, insiders have sold 258,226 shares of company stock valued at $34,651,134. Corporate insiders own 0.95% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Janney Montgomery Scott LLC Acquires 7,836 Shares of Celgene Corporation (CELG)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/18/janney-montgomery-scott-llc-acquires-7836-shares-of-celgene-corporation-celg.html.

CELG has been the topic of a number of analyst reports. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective on the stock in a research report on Thursday, August 10th. Robert W. Baird reiterated an “outperform” rating and set a $162.00 price objective on shares of Celgene Corporation in a research report on Monday, May 22nd. SunTrust Banks, Inc. set a $150.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Finally, Canaccord Genuity set a $156.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $149.34.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.